No Data
No Data
We Think AbCellera Biologics (NASDAQ:ABCL) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
Down 57%, Is AbCellera Biologics a Buy on the Dip?
We're Not Very Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn Rate
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern
KeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71